retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity The Road towards Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Receptor - An Update Retatrutide Severe Obesity Trial Shows

doi: 10.1016/j.clim.2017.05.017

Recent study shows that overactivation of MYC detected in ALS astrocytes induce alterations in EV release and these alterations trigger astrocyte-to-neuron miscommunication, resulting in reduced support of neighboring neurons (Fioretti et al., 2025)

Not perfect, but far less waste than 4mg unused

Indias GLP-1 market semaglutide plus Eli Lillys tirzepatide was worth about 571 crore in 2024

Yes, of course, confirms Danones Esser

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity